Nystatin (Nystatin) Patent Expiration, LOE Window & CMS Spending

Nystatin (Nystatin) by Multi-Source Generic Manufacturers: Multi-Source Generic Molecule, 33 AB generics, $83.6M 2024 CMS Part D & Medicaid spend, and 7 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMulti-Source Generic Manufacturers
FDA Application & PathwayReconciled (ANDA)
Exclusivity / Cliff HorizonMulti-Source Generic Molecule
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors33
2024 CMS Total Public Spend$83.6M
2024 Medicare Part D Spend$53.0M
2024 Medicaid Spend$30.6M
Reported Wholesale Price Change (CA SB 17)7 WAC filings (max 77.0% 2-yr change)